Peptide Medicine's Gray Market Is Closing. Here's What Comes Next.
The gray-market peptide ecosystem — BPC-157, TB-500 — is formalizing under regulatory pressure. What that shift means for biohackers who depend on it.
Peptides: Peter Attia's Framework for Separating Science from Marketing
Peter Attia's episode #403 gives biohackers a rigorous 5-question test for evaluating peptides — and most gray-market compounds fail at question one.
Nuritas' AI-Discovered Peptides Are Now in Frozen Yogurt — and 31 Countries
Nuritas uses AI to discover functional peptides from plant proteins, then validates them through clinical research. At IFT FIRST 2026, PeptiStrong arrived in frozen yogurt format. What this means for functional nutrition.
Elysium Health Launches Physician-Led Longevity Program — Moving From Supplements to Clinical Care
Elysium's new Elysium Longevity Institute combines NAD+ protocols, peptides, and longitudinal data tracking under physician oversight. The shift signals a broader move in longevity from consumer supplementation to integrated clinical programs.
Peptide Telehealth in 2026: The GLP-1 Distribution Model Reaches Longevity
LifespanningRx's partner program brings compounded peptide protocols to independent clinicians in 24 hours — the same telehealth model that mainstreamed GLP-1.
Peptides: Peter Attia Separates the Science From the Hype in AMA #83
BPC-157 has three small studies with no control groups. TB-500 and GHK-Cu have animal data only. Peter Attia's AMA #83 maps what the evidence actually shows — and why the regulatory picture is shifting fast.